RPMI-8226 SMAD/TGFbeta Reporter (Luc) stable cell line

RPMI-8226 SMAD/TGFbeta Reporter (Luc) cells are derived from the human myeloma RPMI-8226 cell line by stably integration of a SMAD/TGFbeta firefly luciferase reporter construct. The RPMI-8226 cell line is a valuable tool for understanding multiple myeloma and developing new treatments, including CAR-T (chimeric antigen receptor T-cell) therapy. RPMI-8226 SMAD/TGFbeta Reporter (Luc) cells stably express firefly luciferase under the control of the SMAD/TGFbeta response elements, can be used for monitoring the activity of TGF?/SMAD signaling pathway.